Csl Limited · ASX:CSL
Csl — Macquarie Australia Conference 2022
17 slides from Csl's conference presentation, May 3, 2022
Slide 1: Presentation at Macquarie Australia Conference 2022
For personal use only For immediate release 3 May 2022 Presentation at Macquarie Australia Conference 2022 Please find attached a presentation to be given by Ms Joy Linton, CSL's Chief Financial Officer at the Macquarie Australia Conference 2022. Authorised by Fiona Mead Company Secretary For furthe
Slide 2: CSL Limited Macquarie Conference
For personal use only CSL Limited Macquarie Conference 3 May 2022 Joy Linton CFO
Slide 3: Important Notice and Disclaimer
For personal use only IMPORTANT NOTICE AND DISCLAIMER This presentation contains summary information about CSL Limited (ACN 004 089 936) and its related bodies corporate (together, CSL) and CSL's activities as at the date of this presentation. It is information given in summary form only and does no
Slide 4: CSL – Leading Global Biotech
CSL – Leading Global Biotech For personal use only 5th Largest Global Biotech Global #1 in protein therapies 8 Manufacturing Sites Across 6 Countries ~$37 billion industry Bern, Broadmeadows, Marburg, Kankakee, Wuhan, China Liverpool, UK Switzerland Melbourne, Germany Illinois, United Global #2 in i
Slide 5: Back to growth post COVID
For personal use only Plasma collections Pathway improving, now circa pre- COVID levels Digital transformation underway back to growth Continued investment in capacity expansion post Product demand limited by supply expected to COVID alleviate Cluster of late stage R&D programs Gross margin expected
Slide 6: COVID - headwind for CSL Behring and tailwind for Seqirus
COVID - headwind for CSL Behring and tailwind for Seqirus For personal use only % CSL Behring Gross Margin % Seqirus Gross Margin 70 60 65 58 60 56 55 54 50 52 45 50 40 FY19 FY20 FY21 1H22 FY19 FY20 FY21 1H22 5
Slide 7: CSL Behring Margin Development
CSL Behring Margin Development For personal use only Other Fixed & Variable Covid Pressures Looking Forward Costs Donor • Higher donor fees • Donor mix management Testing Fees • New donor campaigns • Improvement in plasma volume reducing fixed cost Labour • Competitive US employment per unit environ
Slide 8: Modernizing Plasma via Technology
Modernizing Plasma via Technology For personal use only 01 02 03 Pre-screen Health Check Donation • Prescreening via app • Improve time and efficiency of • Reduce total donation time > 30% • Bypass the kiosk with a Self- the pre-donation health check • RIKA rollout Administered Health History by tak
Slide 9: Capex Growth Driven
Capex Growth Driven For personal use only US$m US$b Capex Revenue 1,400 12 1,200 10 1,000 8 • 60-70% in growth capex 800 v maintenance capex 6 600 over the last 5 years 400 4 • 9% CAGR in capex 200 2 supports 10% CAGR in sales over the last 5 - - years • FY22 expected to be Maint Growth Revenue ~$1.
Slide 10: Key Capital Projects
Key Capital Projects Completion Timeline For personal use only FY22 FY23 FY24 FY25 FY26 FY27 Marburg Base Frac Broadmeadows: Mod 1 & 2 Broadmeadows: Mod 3 Future Base Frac Zemaira Fill/Finish – Thermo Fisher Bulk & Future IG Modules Finishing Broadmeadows Albumin Expansion Lengnau Plasma Centers (Co
Slide 11: Cluster of late stage R&D programs
Cluster of late stage R&D programs For personal use only FY23- FY26 Garadacimab CSL112 Adjuvanted Cell Anti-FXIIa (HAE) ApoA-1 (AMI) Culture Influenza Vaccine HIZENTRA® (aQIVc) (DM) Clazakizumab Anti-IL-6 (AMR) IDELVION® sa-mRNA China (Haem B) Influenza Vaccine CSL964 AAT (GvHD (sa-mRNA) EtranaDez T
Slide 12: Vifor Pharma Acquisition
Vifor Pharma Acquisition For personal use only Overview of Vifor Pharma • World leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of kidney disease and iron deficiency • Unique joint company VFMCRP with Fresenius Medical Care, global leade
Slide 13: Strategic Rationale for the Vifor Pharma Acquisition
Strategic Rationale for the Vifor Pharma Acquisition For personal use only Combined CSL + Vifor Pharma Strengthens CSL’s Value Driven Strategy Revenue (1H22)2 1 Adds a durable and growing business with leadership positions across complementary and adjacent franchises, delivering greater benefit to p
Slide 14: Capital Structure
Capital Structure For personal use only Balanced Share Register Debt Maturity Profile US$m Pre 144A Post 144A Weighted Average 2,000 5.3 years 9.7 years Tenor Weighted Average 2.45% 2.90% Cost of Debt Private 1,500 Aust Inst 1,000 Asia Inst 500 EU/UK North Inst America Inst 0 FY22 FY24 FY26 FY28 FY3
Slide 15: Our Sustainability Strategy
Our Sustainability Strategy For personal use only • Sustainability Strategy approved by the Board in 2021 • Executive Sustainability Committee representing all areas of the business CSL is committed to a • CSL has identified ten focus areas across 3 key strategic pillars: healthier world. Our ‒ Envi
Slide 16: Growth Catalysts
Growth Catalysts For personal use only LONG-TERM MID-TERM • CSL112 • Vifor Pharma • aQIVc NEAR-TERM • Garadacimab • Self amplifying mRNA • Plasma Collections • RIKA • Transplant • RIKA • EtranaDez • FLUCELVAX® paediatric 15
Slide 17: CSL Contacts
For personal use only CSL Contacts Mark Dehring VP Investor Relations +61 3 9389 3407 mark.dehring@csl.com.au Bernard Ronchi Investor Relations +61 3 9389 3470 bernard.ronchi@csl.com.au Stephen McKeon Investor Relations +61 3 9389 6798 stephen.mckeon@csl.com.au